Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bayer Sues Watson Over Patent for Beyaz Birth Control Pill

A unit of Bayer AG, Germany’s largest drugmaker, sued Watson Pharmaceuticals Inc., accusing the generic-drug maker of violating a patent for Beyaz birth control pills.

Watson, based in Parsippany, New Jersey, is trying to develop a copy of Beyaz in violation of the patent, Bayer Pharma AG and partner Merck & Cie claimed today in court papers filed in U.S. District Court in Wilmington, Delaware.

Bayer and Merck “are entitled to an award of damages and treble damages for any commercial sale or use” of Watson’s generic version of Beyaz, the companies said.

Bayer, of Leverkusen, Germany, asked a judge to ban the sale of any Watson birth control product based on the patent.

Watson plans to challenge the validity of the patent, Charlie Mayr, a spokesman for Watson, said in a telephone interview today.

The lawsuit “initiates the formal process of challenging the patent on the product,” Mayr said.

The case is Merck Cie v. Watson Pharmaceuticals Inc., 12-cv-00161, U.S. District Court, District of Delaware (Wilmington).

To see the patent, click: 6,153,401.

-- With assistance from Phil Milford in Wilmington, Delaware. Editors: Michael Hytha, Charles Carter

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.